Innovative Medtech, INC
Market Movers (8-K)
OTC.Pink
AnTix Holdings, Inc. has significantly revised its agreement with Ticketbash, acquiring only a non-exclusive license to source code for $469,500, a substantial reduction from the original asset purchase.
Worse than expected
OTC.Pink
Innovative MedTech, Inc. officially changed its corporate name to AnTix Holdings, Inc. effective September 19, 2025.
OTC.Pink
Innovative MedTech enters into a securities purchase agreement for a $85,000 convertible note to fund business development and working capital.
Worse than expected
Capital raise
OTC.Pink
Innovative MedTech, Inc. has entered into two high-interest convertible promissory note agreements totaling $83,000 in net funding, indicating a reliance on expensive financing for general working capital.
Capital raise
Worse than expected
OTC.Pink
Innovative MedTech, Inc. announced a significant strategic pivot, amending its acquisition terms for event ticketing platform Ticketbash and divesting its healthcare subsidiaries, Sarah Adult Day Services and Sarah Day Care Centers, for $300,000.
Delay expected
Worse than expected
Capital raise
OTC.Pink
Innovative MedTech, Inc. has entered into an agreement to acquire the assets of Grand Concierge LLC, d/b/a Ticketbash, focusing on event ticket pricing and related AI development, through a combination of stock issuance, milestone payments, and revenue royalties.
Quarterly Earnings (10-Q)
OTC.Pink
Innovative MedTech's Q3 2025 filing reveals a net loss, going concern uncertainty, and details of the Ticketbash asset acquisition.
Delay expected
Worse than expected
Capital raise
OTC.Pink
Innovative MedTech reports a significant increase in net loss for the quarter ended December 31, 2024, driven by higher operating expenses and strategic shifts, including the planned sale of its SarahCare subsidiaries.
Worse than expected
Capital raise
OTC.Pink
Innovative MedTech's Q1 2024 results show a significant increase in net loss compared to the same period last year, driven by higher operating expenses.
Worse than expected
Capital raise
OTC.Pink
Innovative MedTech's Q3 2024 results show a significant increase in net loss compared to the same period last year, driven by higher operating expenses.
Worse than expected
Capital raise
OTC.Pink
Innovative MedTech's Q3 2024 report reveals a net loss, ongoing liquidity concerns, and a new licensing agreement, alongside management changes.
Worse than expected
Capital raise
OTC.Pink
Innovative MedTech, Inc. released its second quarter 2024 financial results, showing a decreased net loss and increased revenue compared to the prior year period.
Worse than expected
Delay expected
Capital raise
Annual Reports (10-K)
OTC.Pink
AnTix Holdings, formerly Innovative MedTech, Inc., reported a net income of $1.27 million for fiscal year 2025, driven by the sale of its SarahCare subsidiaries and a strategic pivot to AI-driven ticketing services.
Delay expected
Capital raise
Better than expected
OTC.Pink
10-K: Innovative MedTech Reports $7.9 Million Net Loss in Fiscal Year 2024 Amidst Operational Challenges
Innovative MedTech, Inc. reported a significant net loss of $7.9 million for the fiscal year ended June 30, 2024, alongside increased operating expenses and ongoing financial challenges.
Delay expected
Capital raise
Worse than expected
Insider Trading (Form 4)
OTC.Pink
Michael Jordan Friedman, a director, 10% owner, and President of Innovative Medtech, Inc., acquired 6,500,000 shares of common stock to satisfy accrued salary.